Clinical bottom line
Modulating autophagy represents a promising, yet still investigational, therapeutic approach in autoimmune diseases. Emerging therapies targeting autophagy pathways aim to restore immune homeostasis by regulating cellular degradation and antigen presentation processes implicated in autoimmunity. Current evidence from preclinical and early-phase clinical studies suggests potential efficacy in reducing autoimmune inflammation and tissue damage, but safety profiles and long-term outcomes remain incompletely characterized. Clinicians should consider autophagy modulation as a putative adjunct or alternative strategy in refractory autoimmune conditions pending further validation.
What the evidence shows
Autophagy, a conserved intracellular degradation pathway, plays a critical role in immune regulation by controlling antigen processing, cytokine production, and lymphocyte survival. Dysregulated autophagy has been implicated in the pathogenesis of multiple autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis (Chatenoud et al., 2020). Therapeutic strategies targeting autophagy aim to either enhance or inhibit this pathway to restore immune tolerance.
Preclinical models demonstrate that pharmacologic modulation of autophagy can attenuate autoimmune pathology. For example, autophagy enhancers have shown efficacy in reducing inflammatory cytokine release and promoting regulatory T cell function, while autophagy inhibitors may limit autoreactive lymphocyte survival (Chatenoud et al., 2020). These mechanistic insights have catalyzed the development of novel agents, including small molecules and biologics, designed to selectively modulate autophagy components.
Clinical data remain limited but encouraging. Early-phase trials of autophagy modulators in autoimmune diseases report signals of clinical benefit with manageable safety profiles, though sample sizes are small and follow-up short (Chatenoud et al., 2020). The heterogeneity of autoimmune disorders and patient populations complicates interpretation, underscoring the need for biomarker-guided patient selection and rigorous trial design.
Notably, autophagy-targeted therapies may complement existing immunomodulatory agents by addressing intracellular pathways not directly targeted by conventional biologics or JAK inhibitors. This novel mechanism of action could provide therapeutic options for patients with refractory disease or intolerant to current treatments (Chatenoud et al., 2006).
Caveats and uncertainty
Despite promising preclinical and early clinical findings, several uncertainties temper enthusiasm for routine clinical use of autophagy modulators in autoimmunity. First, the dual role of autophagy in immune activation and suppression complicates therapeutic targeting; inappropriate modulation could exacerbate disease or increase infection risk (Chatenoud et al., 2020). Second, long-term safety data are lacking, particularly regarding immunosuppression-related adverse events and malignancy risk.
The complexity of autophagy pathways and their crosstalk with other cellular processes necessitate precise targeting to avoid off-target effects. Current agents often lack specificity, raising concerns about unintended consequences. Moreover, robust biomarkers to monitor autophagy activity and predict response are not yet established, limiting personalized therapy approaches.
Finally, the majority of evidence derives from small, early-phase studies or preclinical models, with few large randomized controlled trials completed. This limits confidence in efficacy estimates and generalizability across diverse autoimmune diseases and patient populations.
How this may change practice
If ongoing and future studies confirm safety and efficacy, autophagy modulation could emerge as a valuable addition to the therapeutic armamentarium for autoimmune diseases. Clinicians may consider these agents particularly in patients with refractory disease or those who have contraindications to existing immunosuppressants.
Integration of autophagy modulators will likely require development of companion diagnostics to identify patients most likely to benefit and to monitor treatment response. Combination strategies with current biologics or small molecules may enhance efficacy while mitigating risks.
In the near term, awareness of autophagy’s role in autoimmunity may inform clinical trial enrollment and encourage multidisciplinary collaboration between immunologists, pharmacologists, and translational researchers. However, routine clinical implementation awaits confirmatory phase 3 trials and regulatory approvals.